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Background. Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence,
their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in
cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating
hydralazine, plus the HDAC inhibitor magnesium valproate, were added to neoadjuvant doxorubicin and cyclophosphamide in
locally advanced breast cancer to assess their safety and biological efficacy. Methodology. This was a single-arm interventional
trial on breast cancer patients (ClinicalTrials.gov Identifier: NCT00395655). After signing informed consent, patients were typed
for acetylator phenotype and then treated with hydralazine at 182 mg for rapid-, or 83 mg for slow-acetylators, and
magnesium valproate at 30 mg/kg, starting from day –7 until chemotherapy ended, the latter consisting of four cycles of
doxorubicin 60 mg/m
2 and cyclophosphamide 600 mg/m
2 every 21 days. Core-needle biopsies were taken from primary breast
tumors at diagnosis and at day 8 of treatment with hydralazine and valproate. Main Findings. 16 patients were included and
received treatment as planned. All were evaluated for clinical response and toxicity and 15 for pathological response.
Treatment was well-tolerated. The most common toxicity was drowsiness grades 1–2. Five (31%) patients had clinical CR and
eight (50%) PR for an ORR of 81%. No patient progressed. One of 15 operated patients (6.6%) had pathological CR and 70%
had residual disease ,3 cm. There was a statistically significant decrease in global 5
mC content and HDAC activity. Hydralazine
and magnesium valproate up- and down-regulated at least 3-fold, 1,091 and 89 genes, respectively. Conclusions. Hydralazine
and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors.
Doxorubicin and cyclophosphamide treatment is safe, well-tolerated, and appears to increase the efficacy of chemotherapy. A
randomized phase III study is ongoing to support the efficacy of so-called epigenetic or transcriptional cancer therapy.
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Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer. PLoS ONE 1(1): e98. doi:10.1371/
journal.pone.0000098
INTRODUCTION
Aberrant gene transcriptions resulting from epigenetic changes are
frequent events in the molecular pathogenesis of malignant trans-
formation. DNA hypermethylation and histone deacetylation are
critical for determining a closed chromatin structure responsible for
or related with aberrant gene transcription in malignancies [1]. In
counterpoint to genetic defects, the reversible nature of epigenetic
aberrations constitutes an attractive therapeutic target; hence,
a number of DNA methylation and histone deacetylase (HDAC)
inhibitors are undergoing preclinical testing in combination for
cancer therapy because it is clear that these drugs exert a synergistic
effect on gene expression [2,3] and tumor growth [4–8]. To date,
only a limited number of clinical trials has been reported using both
a demethylating and an HDAC inhibitor for treatment of hematolo-
gical [9] and solid tumors [10]. Interestingly, preclinical reports have
underscored that DNA methylation and HDAC inhibitors also
possess the ability to potentiate radiation and chemotherapy [11–
15]. In addition, it is known that chemotherapy resistance_either
innate or acquired_requires expression changes in a large number of
genes for its development; therefore, it has been hypothesized that
epigenetic-mediated changes could be the responsible driving force
for chemotherapy resistance; thus, epigenetic therapy has the
potential to revert chemotherapy resistance [16].
In breast cancer, there is substantial evidence demonstrating the
importance of epigenetic mechanisms in transcriptional regulation
of critical tumor suppressor and growth regulatory genes. These
genes include those that play crucial roles in DNA repair, cell-
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contribute to breast cancer tumorigenesis, metastasis, and re-
sistance to therapy [17–20]. Thus, clinical testing of a combination
of epigenetic agents together with classical cytotoxic chemotherapy
in breast cancer appears desirable.
Primary systemic, neoadjuvant, or preoperative therapy is the
standard of care in patients with operable and locally advanced
breast cancer [21]. Comparable outcomes have been found for
pre- and post-operative administration of various cytotoxic
regimens [22,23]; however, pre-operative therapy has the
advantage of the assessment of pathological tumor response,
which has been correlated with improved survival [24,25].
Additionally, it provides an opportunity to evaluate biological
markers after treatment. Therefore, in this proof-of-principle study
we intended to evaluate the safety and biological and clinical
efficacy of the epigenetic agents hydralazine and magnesium
valproate plus neoadjuvant doxorubicin and cyclophosphamide in
locally advanced breast cancer.
METHODS
Patients
Eligible patients were 18 years of age and older, with histologically
proven invasive T2-3, N0-2, and M0 (stages IIB–IIIA) breast
carcinoma. Additional eligibility requirements included Eastern
Cooperative Oncology Group performance status #2, absolute
leukocyte count $4,000/mm
3, platelets $100,000/mm
3, hemo-
globin $9.0 g/dL, total bilirubin, aspartate amino transferase and
alanine amino transferase #1.5 the upper normal limit, creatinine
#1.2 mg/dL or a calculated creatinine clearance of $60 mL/
min, and written informed consent.
Patients were excluded if they referred a history of allergy to
sulfas, hydralazine, or magnesium valproate, past or present
condition of rheumatic disease, central nervous system disease,
heart failure from aortic stenosis and postural hypotension as
diagnosed by a physician, previous use of the experimental drugs,
as well as if patients were pregnant or breast-feeding. Other
exclusion criteria included uncontrolled systemic disease or
infection. The protocol was approved by the Institutional Review
Boards of the Instituto Nacional de Cancerologia Mexico and
carried out in accordance with the Declaration of Helsinki, good
clinical practices, and local ethical and legal requirements.
Treatment plan
Once informed consent was signed, patients received a single oral
500-mg dose (two 250-mg tablets) of sulfamethazine early in the
morning, and urine was collected within the ensuing 6 h for
acetylator-status phenotyping, which was carried out as reported
[26]. Afterward, patients began treatment (day –7) with a daily
dose of a slow-release formulation of hydralazine tablets contain-
ing either 182 mg for rapid-acetylators or 83 mg for slow-
acetylators. Magnesium valproate tablets of 700 mg were also
administered as a slow-release formulation at a dose of 30 mg/Kb
t.i.d. Both hydralazine and magnesium valproate were adminis-
tered from day –7 until the last day of the fourth chemotherapy
cycle.
Chemotherapy
Chemotherapy consisted of four cycles of doxorubicin 60 mg/m
2
and cyclophosphamide 600 mg/m
2 at day 1 every 21 days.
Antiemetic premedication was intravenous (i.v.) dexamethasone
16 mg and ondansetron 16 mg.
Therapy duration and dose modifications
Patients received hydralazine and magnesium valproate until the
last chemotherapy cycle, and were discontinued if the patient was
unable to tolerate these despite dose modification, if the patient
developed concurrent illness, or if the patient underwent changes
in medical condition rendering them unacceptable for further
treatment. Chemotherapy administration was delayed for 1 or 2
weeks in the event of any grade 3 or 4 hematological and non-
hematological toxicity. In all these cases, however, hydralazine
and magnesium valproate were continued. Only the dose of
magnesium valproate was reduced 25% for grade 3 drowsiness,
and was continued at the reduced level throughout the ensuing
chemotherapy treatment. Routine or prophylactic use of colony
stimulating factors was not allowed during treatment. Nonetheless,
growth factor support was permitted to treat a neutropenic event.
If the disease progressed during pre-operative therapy, chemo-
therapy was discontinued and patients underwent immediate
surgery or radiation therapy. After final clinical-response assess-
ment, patients were required to be operated on between 14 and 28
days after the last chemotherapy application. Thereafter, all
patients received standard radiotherapy of the remaining breast
tissue or to the chest wall. Adjuvant weekly paclitaxel 80 mg/m
2
was administered for 12 weeks in patients with positive nodes after
surgery. HER2-positive patients also received adjuvant trastuzu-
mab. Tamoxifen 20 mg/day was administered in estrogen
receptor-positive patients.
Assessment
Baseline work-up included a complete history and physical
examination, bilateral mammography and sonography of the
breast, chest x-ray, liver ultrasound (US), and bone scintigraphy.
Histologically, the tumor was evaluated with Scarff-Bloom-
Richardson grading; HER2 and hormone receptors were assayed
by immunohistochemistry. Laboratory assessment consisted of
complete blood cell count and blood chemistry. Tumor assessment
was performed within 2 weeks prior to initiation of transcriptional
therapy. Clinical evaluation of palpable tumor and lymph nodes
was repeated before each cycle and before surgery.
The primary end-points were to evaluate the safety of cytotoxic
chemotherapy associated with hydralazine and magnesium
valproate, as well as to evaluate changes in DNA methylation,
HDAC inhibition and global gene expression before and after
treatment. The secondary end-point was to evaluate clinical and
pathological response after the fourth chemotherapy course.
Clinical complete response (CR) response was defined as complete
disappearance of all tumor signs in the breast and was assessed by
both palpation and by the most appropriate imaging method.
Partial response (PR) was defined as a reduction in the product of
the two largest perpendicular diameters of primary-tumor size by
50% or more. In patients with multifocal or multicentric disease,
solely the lesion with the largest diameter was assessed. Stable
disease (SD) was defined as no significant increase or decrease in
tumor size, and progressive disease was defined as the de-
velopment of new, previously undetected lesions or $25%
increase in the size of a pre-existing lesion. Pathological complete
response (pCR) was defined as no microscopic evidence of residual
viable tumor cells in breast and axillary lymph nodes. Toxicity
during chemotherapy was evaluated according to common toxicity
criteria (CTC) of National Cancer Institute (NCI) version 2.0.
Clinical samples
Core-needle biopsies were taken from primary breast tumors at
diagnosis and after 7 days of treatment with hydralazine and
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cyclophosphamide. Part of the biopsy was sent to the Institution’s
Pathology Department for routine hematoxilin and eosin di-
agnosis. The remaining biopsy specimen was immediately frozen
at 220uC for biological analyses. In addition, a blood sample was
drawn from the arm by venipuncture to obtain plasma and the
mononuclear cell fraction.
Nucleic acid extraction
Genomic DNA from tumors and peripheral mononuclear blood
cells was obtained with the standard method of proteinase-K
digestion and phenol-chloroform extraction. RNA from tumors
was obtained using the TriReagent RNA extraction kit (Gibco
BRL Grand Island, NY, USA) following manufacturer instructions.
RT-PCR
Primers for NDUFA13 were forward 59aatgcaagaaccaaggcgagtca-
c39and reverse 59aggcatgtcctgcttcacctttga3, and for DAPPER, these
were gcgaagagatgctggtttgt39and 59tgagagactcaaggtcgcc39. Anneal-
ing temperatures were 60 and 55uC for 35 cycles. Products were
electrophoresed and visualized under ultraviolet (UV) light.
Global DNA methylation
Quantification of genomic 5-methylcytosine from peripheral blood
DNA was performed by capillary electrophoresis, as previously
described [27]. Relative methylation of each DNA sample was
taken as the percentage of
mC in total cytosine:
mC peak
area6100/(C peak area+
mC peak area).
Histone deacetylase assay
Assays were performed using the colorimetric HDAC activity
assay from BioVision (BioVision Research Products, Mountain
View, CA, USA) according to manufacturer instructions, as
described [28].
Valproic acid plasma levels
Valproic acid was measured in plasma using a fluorescence
polarization immunoassay (FPIA) technology, as previously de-
scribed [28].
Hydralazine plasma levels
Hydralazine was determined in plasma by high-performance
liquid chromatographic (HPLC) assay, as previously described
[29].
Microarray analysis
We used the Amersham (Piscataway, NJ, USA) CodeLink system
containing 55,000 gene 30-mer oligonucleotide probes. Target
preparation, microarray hybridization, post-hybridization proces-
sing and scanning, and normalization were done essentially as
described [13]. Gene expression differences induced by epigenetic
treatment were analyzed by comparing pre- and post-treated
clinical samples versus normal breast serial analysis of gene
expression (SAGE) libraries obtained from the SAGE public
website. We included only libraries obtained from normal tissues
and with a total amount of sequenced tags. Median expression
values for each tag were calculated. To avoid errors in matching
tag to Unigene cluster, we considered only tags of .30,000 for
which a unique Unigene cluster match was found. To reduce
redundancy due to different cluster ID-associated tags, we
eliminated these repetitive Unigene IDs. Data values for each
sample were normalized between the two platforms against the
median of normal breast SAGE libraries, and Log2-based
expression ratios were obtained. As unsupervised analysis, we
performed hierarchical clustering and principal component
analyses to group genes and samples on the basis of their
similarities in expression as an initial analysis. An average linkage
hierarchical-clustering technique was used in which the measure-
ment of similarity was Spearman rank correlation among the
samples’ transcription profiles. Log-2 expression ratios were
filtered to find genes with a 3-fold minimum expression ratio.
Hierarchical clustering analyses and principal component analyses
were performed by means of the Genesis program [30].
A supervised analysis was also performed to determine genes
that were significantly differentially expressed between pre- and
post-epigenetic treatment in clinical samples using significance
analysis ofg microarrays. This method involves testing each gene
one at a time and then performing 100 permutation tests to
estimate the false- discovery rate that arises from input genes [31].
We selected the number of significant genes corresponding to
a target false-discovery rate of 0.16.
Statistical analysis
Comparisons between biological measurements before and after
treatment were evaluated by Wilcoxon or unpaired t test. Analysis
of the comparison between serum levels of hydralazine throughout
treatment according to acetylator phenotype was carried out by
independent Student t test. A p value ,0.05 was considered
significant.
RESULTS
Patients
The flow diagram of the trial is shown in Figure 1. Sixteen patients
were included in this study. Patient characteristics are listed in
Table 1. Mean age was 47 years (range, 38–67 years), 68 and 32%
were stages IIIA and IIB, respectively, and median tumor size was
5 cm (range, 3–12 cm). All patients had clinically positive nodes
with median nodal size of 2 cm (range, 1–5 cm). The majority of
tumors (80%) were ductal carcinomas, and 80% were intermedi-
ate- and high-grade tumors; 77% were estrogen receptor-positive
and 30% were HER2- positive.
All patients received four cycles of doxorubicin and cyclophos-
phamide plus hydralazine and magnesium valproate as planned.
In addition, all patients were evaluated for clinical response and
toxicity, but there were only 15 pathological assessments of the
response, as one patient refused surgical treatment. Analysis of
DNA methylation, HDAC activity before and after pre-treatment
days with hydralazine and magnesium valproate was performed in
five patients, whereas only three patients could be analyzed for
global expression profiling of tumors. Hydralazine and valproic
acid plasma levels were measured at several points during the
protocol.
Clinical Response
The sixteen patients were evaluable for clinical response. Five
(31%) patients had complete response and eight (50%), partial
response, for an overall response rate of 81%. Three patients had
stable disease and none progressed (Table 2).
Pathological Response
Fifteen patients underwent surgery. One patient (6.6%) had
pathological complete response. However, in 70% of cases residual
disease was ,3 cm, 33% of cases had pathological negative lymph
nodes, and no case had extranodal extension (Table 2).
Epigenetic Therapy of Cancer
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The treatment was well-tolerated in general. All patients received
four cycles of pre-operative chemotherapy; in total, 64 cycles were
administered. Hematological toxicity was the most common side
effect, neutropenia grade 3/4 observed in 35% of cases and
anemia grade 3/4 in 15% of cases. No episodes of grade 3/4
thrombocytopenia were registered. Only two patients presented
febrile neutropenia. No toxic deaths were registered. Regarding
non-hematological toxicity, drowsiness was the most frequent side-
effect; it was observed in 31% of cycles, nonetheless in the vast
majority, of grade 1 severity. Other side effects were tremor,
edema, fatigue, nausea/vomiting, and headache, mainly grades 1
and 2 (Table 3).
DNA Methylation
Global DNA methylation was assessed by capillary electrophoresis
in DNA extracted from the peripheral blood of five patients. The
results show in all cases a significant reduction in 5
mC content,
varying from 0.7–2.59% decrease. Mean 5
mC in the five pre-
treatment samples was 5.71% (standard deviation [SD], 1.43),
which decreased to 4.2% (SD, 0.95). This difference was
statistically significant (p=0.043) (Figure 2).
Histone Deacetylase Activity
HDAC enzymatic activity was tested in protein extracts from the
peripheral blood of five patients. As shown in Figure 3, there was
a reduction in enzymatic activity in these five patients as
determined by optical density (OD)-unit absolute values. Higher
and lower decreases were 0.3845 and 0.0175, for a mean decrease
of 0.1624. This difference was statistically significant (p=0.042).
Figure 1. Flow diagram of the trial.
doi:10.1371/journal.pone.0000098.g001
Table 1. Clinicopathological characteristics
......................................................................
Variable Number (%)
Age (median) 47 (38–67)
Staging (TNM)
IIB 5 (31.3)
IIIA 11 (68.7)
Histology
Ductal 14 (87.5)
Lobulillar 1 (6.3)
Mixed 1 (6.3)
Tumor size
Median 5 cm
Range 3–12 cm
Histological grade
1 1 (6.3)
2 8 (40)
3 7 (47.4)
Lympho-vascular invasion
Present 5 (31.3)
Absent 11 (68.7)
Estrogen Receptor
Positive 11 (68.7)
Negative 5 (31.3)
HER2 (Herceptest ++/+++)
Positive 4 (25)
Negative 12 (75)
Menopause status
Premenopause 9 (56)
Postmenopause 7 (44)
Node status (TNM)
N1 9 (56)
N2 7 (44)
Node size
Median 2 cm
Range 1–5 cm
doi:10.1371/journal.pone.0000098.t001
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Table 2. Response to treatment
......................................................................
Clinical Response Number %
Complete 5 31.2%
Partial 8 50%
Stable 3 18.8%
Progression 0 0%
Overall 11 81.2%
Pathological response Number %
Complete 1 6.6%
Residual ,3 cm 11 73.3%
Residual .3c m 3 2 0 %
There were 16 and 15 patients who were evaluable for clinical and pathological
response, respectively.
doi:10.1371/journal.pone.0000098.t002
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Plasma samples for measuring valproic acid concentration
throughout treatment were available for 14 patients. Mean
concentrations varied from 78.5 mg/mL–100.3 mg/mL, for an
overall mean of 87.5 mg/mL. There was a continuous decrease in
mean concentrations from the beginning to the end of treatment;
nevertheless, the sole statistically significant difference was
observed when first and the last determinations were compared
(p=0.0118) (Table 4).
Hydralazine Plasma Levels
Plasmatic levels of hydralazine were analyzed in 10 patients in
whom plasma samples were available at different time-points
during treatment. Distribution of these patients according to
acetylator phenotype was four and six for slow and rapid,
respectively. Mean plasma levels of hydralazine ranged from
204.8–275.1 ng/mL for rapid-acetylators, whereas these mean
values were 252.1–344.2 ng/mL in slow- acetylators. Overall
means were 246 and 299 ng/mL, respectively, which were not
statistically significant different (p=0.2445) (Table 5).
Gene Expression
A total of 3,117 genes were found up and down-regulated in
clinical samples as compared with normal breast tissue. Figure 4
shows cluster analysis of microarray data. As can be observed,
expression profile of post-treatment samples cluster together. This
was also shown in a principal component analysis, which is an
exploratory multivariate statistical technique that allows identifi-
cation of variables in a multidimensional data set that explains
differences or similarities between observations better than
hierarchical clustering (Figure 5). With regard to changes in
global gene expression observed after hydralazine and valproate
treatment, the pre-treatment sample was compared against three
post-treatment samples (GEO accession number GSE6304). The
number of genes up- or down-regulated by an at least 3-fold
difference was 1,091 and 89, respectively (Tables S1 and S2).
Table 6 lists some selected genes found up- and down-regulated
after treatment. To further assess the up-regulating effect of
hydralazine and magnesium valproate, NDUFA13 and DRAPER
gene expression was assessed by RT-PCR in the single patient in
whom RNA from pre- and post-treatment biopsies was available.
As expected, expression of these genes was reactivated (Figure 6).
DISCUSSION
The idea of treating cancer patients with agents able to re-establish
expression of tumor suppressor genes silenced by epigenetic
mechanisms is currently being tested. Clinical trials using
a combination of DNA methylation and HDAC inhibitors have
already shown promising results in hematological neoplasms
[9,10]. Here we report on the safety and the biological and
clinical efficacy of hydralazine and magnesium valproate added to
doxorubicin cyclophosphamide for neoadjuvant treatment of
locally advanced breast cancer.
The results of this proof-of-principle study demonstrate that this
therapy is safe, that it achieves the molecular changes expected
from use of a demethylating and an HDAC inhibitor and appear
to increase the efficacy of conventional cytotoxic agents.
Patients entering the study had IIB- and IIIA-stage disease with
median tumor size and median axillary nodal sizes of 5 and 2 cm,
respectively. Despite this, we observed clinical complete response
in five (31.2%) patients, for an overall response rate of 81%. This
rate is in the upper limit of response rates observed across multiple
Figure 2. Global DNA methylation. The five patients had a reduction in 5mC content varying from 0.722.59% decrease. The mean 5mC in the five
pre-treatment samples was 5.71% (standard deviation [SD], 1.43) which decreased to 4.2% (SD, 0.95). This difference was statistically significant
(p=0.043).
doi:10.1371/journal.pone.0000098.g002
Table 3. Toxicity of treatment from a total of 64
chemotherapy courses in the 16 patients
......................................................................
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Drowsiness 16 (25%) 3 (4.6%) 1 (1.5%) 0
Tremor 2 (3.1%) 0 2 (3.1%) 0
Edema 6 (9.3%) 0 0 0
Fatigue 7 (10.9%) 2 (3.1%) 0 0
Nausea/vomiting 16 (25%) 3 (4.6%) 1 (1.5%) 0
Headache 5 (7.8%) 3 (4.6%) 0 0
Anorexia 2 (3.1%) 0 0 0
Diarrhea 0 2 (3.1%) 0 0
Anemia 3 (4.6%) 8 (12.5%) 2 (3.1%) 0
Neutropenia 10 (15.6%) 15 (23.4%) 9 (14%) 5 (7.8%)
Thrombocytopenia 0 1 (1.5%) 0 0
doi:10.1371/journal.pone.0000098.t003
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responses between 45 and 83% [32]. Regarding the pathological
response, only one of 15 patients (6.6%) achieved complete
response. This response rate is, nonetheless, within the range
expected from four cycles of anthracyclin-based chemotherapy
with rates varying between 3 and 16% [23,25,33–38]. Notwith-
standing this, we have no historical control at our Institution
treated with this regimen to better assess whether addition of
hydralazine and magnesium valproate increased the response.
Nevertheless, a recent study in patients with breast cancer treated
with anthracyclin-based neoadjuvant chemotherapy at a Mexican
institution reports 7% and 45% complete and partial responses,
respectively, none pathological complete [39]. Regarding the
response in axillary nodes at treatment initiation, all patients had
clinically positive nodes, while after therapy we found only 10
patients with pathologically axillary nodes involved. In this regard,
Rouzier et al. recently reported on 152 patients with T1–3 breast
cancer and positive axillary nodes. After neoadjuvant chemother-
apy, 23% had complete disease eradication in axillary lymph
nodes [40]. In the present study, axillary pathological complete
response rate was 33%; however, no cytological confirmation of
pre-treatment status was performed in our study.
Recently, a nomogram based on clinical stage, estrogen
receptor status, histological grade, and number of pre-operative
chemotherapy cycles that had good discrimination and calibration
in training and anthracyclin-treated validation sets has become
available to the public [41]. To obtain further information on the
usefulness of our treatment protocol, data of the 15 patients were
entered into the nomogram, and we found that predicted
pathological complete response rate for our patients was 12%,
whereas the actual rate observed was 6.6%. Nonetheless, the
probability of achieving a pathological residual ,3c m a s
predicted from the nomogram was 39%, but the observed rate
was 73.3%. These results suggest that the addition of hydralazine
and magnesium valproate to the four doxorubicin-cyclophospha-
mide cycles may have increased probability of response.
Regarding the safety of cytotoxic chemotherapy-associated
hydralazine and magnesium valproate, this treatment was well-
tolerated. The only toxicity that could be attributed to the
experimental therapy_specifically, to valproate_was drowsiness in
the majority of patients; however, this was grades 1 and 2, which
by definition do not interfere with patient functioning in daily
living. Only one patient presented grade-3 drowsiness. Regarding
hydralazine, we observed headache and leg edema but no flushing,
hypotension, palpitation, tachycardia, dizziness, or angina pec-
toris, which comprise hydralazine’s cardiovascular effects. The
lack of minor side effects produced by these drugs can be at least
partly due to the slow-release formulation that avoids hydralazine
plasma peaks. Hematological toxicity was within ranges reported
by anthracyclin-based schemas, with no grade 3/4 thrombocyto-
penia, and 15% grade 3/4 anemia; nevertheless, we observed
grade 3/4 neutropenia in 35% of cases, which appears to be
higher than that reported by other authors [23,25,33–38].
Valproic acid is known to induce trilineage hematological toxicity
[42] and to increase the hematological toxicity of a regimen
containing fotemustine and cisplatin [43]; nonetheless, it has also
been reported that this drug stimulates hematopoietic stem cell
proliferation and self-renewal [44]. Whether or not the combina-
Figure 3. Histone deacetylase activity. The five patients assayed showed a reduction in enzymatic activity. In Y axis are the absolute values in optical
density (OD) units. Higher and lower decreases were 0.3845 and 0.0175, for a mean decrease of 0.1624. This difference was statistically significant
(p=0.042).
doi:10.1371/journal.pone.0000098.g003
Table 4. Plasmatic levels of valproic acid in mg/mL
......................................................................
Day 8 Cycle 21 Cycle 2 Cycle 3 Cycle 4 Overall
Mean 100.3 96.9 86.9 81.8 78.1 87.5
SD 20.1 21.8 24.0 19.5 23.1 22.6
Determinations were taken in 14 patients. The difference between the first and
fourth mean concentrations was statistically significant (p=0.0118). SD,
standard deviation.
doi:10.1371/journal.pone.0000098.t004
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Table 5. Hydralazine plasmatic levels according to the
acetylator phenotype (ng/mL)
......................................................................
RAPID
Day 8 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Overall
Mean 204.8 229.3 266.1 192.5 275.1 246.0
SD 135.0 133.4 160.5 110.5 176.9 126.7
SLOW
Day 8 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Overall
Mean 344.2 298.3 252.1 335.1 287.0 299.2
SD 34.3 64.0 154.3 169.8 193.8 132.0
Determinations taken in 10 patients. Four were slow and six were rapid
acetylators. SD, standard deviation.
doi:10.1371/journal.pone.0000098.t005
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induced myelosuppression needs to be further evaluated.
Regarding plasmatic levels achieved with the treatment, it is
remarkable that the hydralazine levels achieved were nearly 3-fold
higher than those commonly observed when hydralazine is used as
an antihypertensive [45]. In our previous phase I study using
hydralazine at doses between 50 and 150 mg/day without
accounting for acetylator phenotype, we observed demethylating
and reactivating effects [46]; hence, the levels observed herein
readily explain the molecular changes observed regarding
methylation and gene expression. In this regard, pharmacokinetic
characterization in healthy volunteers of the slow-release hydral-
azine formulation employed in this study (unpublished data)
demonstrated AUC concentrations of 6,034+1,899 ng/h/mL and
2,751+954 ng/h/mL for slow- and rapid-acetylators, respectively,
using 182 mg regardless of acetylator status. It is noteworthy that
the dose adjustment we chose of 182 mg/day and 83 mg/day for
rapid-and slow-acetylators, respectively, was adequate, because no
statistically significant differences were found in hydralazine
plasmatic levels between both types of patients (means, 246 and
249 ng/mL,respectively). With respect to valproic acid levels, we
found a mean concentration of 87.5 mg/mL, which is within
ranges observed in our previous phase I study demonstrating
histone hyperacetylation and HDAC inhibition, in which mean
concentrations observed were 94.06 mg/mL, 123.46 mg/mL, and
90.93 mg/mL for dose levels of 20, 30, and 40 mg/kg, re-
spectively. Plasma levels progressively decreased until the end of
treatment. However, the mean value in the lowest (four-cycle)
determination was .75 mg/mL, which is an effective concentra-
tion [28].
There is a very large number of in vitro studies demonstrating
global and gene-promoter DNA hypomethylation after treatment
with nucleoside analogs, principally 5-azacytidine and 5-aza-2-
deoxyazacytidine [46]. Interestingly, this hypomethylating effect
has also been achieved in a number of clinical trials employing
these agents in hematological malignancies; in fact, measurement
of this biological effect constitutes a surrogate marker for the
activity of these agents [47]. The same has been observed
regarding H3 and H4 histone hyperacetylation and/or inhibition
of HDAC activity by a number of agents including valproic acid
[48]. Here, we confirmed our in vitro [49,50] and clinical
observations [51] that hydralazine is an effective DNA methyla-
tion inhibitor that led to a statistically significant reduction in the
percentage of 5
mC content in peripheral mononuclear cells after 7
days of treatment. Interestingly, the hypomethylating effect
appears higher, or at least similar, to that achieved by 5-aza-2-
deoxyazacytidine when evaluated by a related quantitative HPLC-
based assay after 7 days of continuous infusion [52]. Other authors
have also demonstrated the ability of hydralazine to hypomethy-
late DNA in other experimental systems [2006, ASCO Procc
Abstr 13131], as well as in a clinical setting. Zafar et al. have
shown that hydralazine used together with neoadjuvant chemo-
therapy decreases DNA methylation in primary tumors of patients
with breast cancer [2006, AACR Procc 2006 Abstr 41].
On the other hand, the ability of valproic acid to hyperacetylate
H3 and H4 histones and to inhibit HDAC has been also
demonstrated in the peripheral blood of patients with hematolog-
ical neoplasms [10,9]. Despite this, it is not totally clear whether
histone hyperacetylation is the sole mechanism for explaining its
antitumor effects; in vitro studies have demonstrated a good
correlation between these phenomena [54]. Our findings of
a significant decrease in histone acetylase activity as measured by
an ELISA assay in five of five patients further support the clinical
use of this agent.
A number of pre-clinical studies have consistently demonstrated
that DNA demethylating agents and HDAC inhibitors, either
alone or in combination, are able to modulate the expression of
a number of genes in ranges varying from 0.5–12% [55,56], and
Figure 4. Hierarchical Cluster Analysis. The cluster shown represents
3,117 genes. Each row represents a gene, whereas each column
corresponds to a tissue sample. The relative abundance of the gene in
the tissue correlates with color intensity (red, induced; green, repressed;
black, no change). On the dendogram, post-treated clinical samples
clustered together.
doi:10.1371/journal.pone.0000098.g004
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[4–8], but also the extent of gene up-regulation [2,3]. We recently
confirmed this synergy between hydralazine and valproic acid
regarding global gene expression by studying colon carcinoma cell
line SW480, in which hydralazine and valproic acid led to up-
regulation of 153 and 178 genes, respectively, whereas the number
of up-regulated genes increased to 352 when used in combination
[13]. These data led us to evaluate gene-expression changes at
a global level by use of the CodeLink microarray system after 7
days of treatment with this combination of epigenetic agents.
Despite that we could only evaluate three patients, among whom
only one yielded sufficient RNA in the pre-treatment sample, our
data clearly demonstrated the ability of these agents to up-regulate
1,091 genes and to down-regulate 89. As this is the first study
evaluating the effect of epigenetic therapy in solid tumors with this
methodology, we have no means of comparison with similar
studies; nonetheless, it is remarkable that the extent of up-
regulation falls well within that expected from in vitro experiments
of global expression, including that performed by our group with
the same method of analysis [13]. It should also be noted that in
two microarray studies performed in primary breast-tumor
samples before and after 24–72 h after chemotherapy, the up-
regulated number of genes is ca 20% of those observed in our
study [57,58]. These data, along with our findings of significant
DNA hypomethylation and HDAC inhibition, strongly indicate
that hydralazine and magnesium valproate up-regulate the
expression of a significant number of genes in a clinical scenario.
Another supportive finding on their reactivating activity was the
unexpected observation that the three post-treatment samples
cluster together (Figures 4 and 5) when the four samples were
compared with gene expression of normal breast.
Regarding the nature of gene-expression changes, Table 6 list
selected genes that showed expression changes (the full list is
supplied as Supporting Information). The data are quite in-
teresting and we emphasize the effect observed in tumor
suppressor gene p53. Hydralazine and magnesium valproate
induced 7.7-fold p53 expression, which confirms that HDACs can
up-regulate p53 gene transcription, as demonstrated with
depsipeptide and trichostatin A [59,60]. Moreover, it has been
shown that p53 induction by HDAC inhibitors may completely
deplete mutant p53, and such a sudden restoration is highly
cytotoxic to cells harboring mutant p53 [59]. On the other hand,
the induction of functional p53 induced by depsipeptide sensitizes
SW-1736 cells to doxorubicin [60]. The modulation of this gene
for therapeutic aims can be better highlighted from studies using
Figure 5. Principal Component Analysis. Principal Component Analysis, showing in three-dimensional space relationship between samples.
doi:10.1371/journal.pone.0000098.g005
Figure 6. Gene expression by RT-PCR. RT-PCR of NDUFA13 and
DAPPER genes in biopsies from the primary tumor showing that these
genes were reactivated after treatment. This corresponds to one of the
three patients whose biopsy (only post-treatment) was analyzed by
microarray and showed over-expression of these genes.
doi:10.1371/journal.pone.0000098.g006
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delivery into tumors by viral vectors, as in a recent study that
demonstrated its potential to increase chemotherapy effects in
patients with breast cancer [62]. On the other hand, we observed
over-expression of IFN-response pathway genes, which have been
found consistently up-regulated by epigenetic drugs in a number of
experimental systems and which increase recombinant interferon-
alpha cytotoxicity [63]. Likewise, epigenetic agents have also been
shown to up-regulate class-I molecules of the major human
histocompatibility complex [64]. Here we show that hydralazine
and magnesium valproate led to a .8-fold up-regulation in class-I
A and -B molecules. This may also have sound therapeutical
implications in the treatment of cancer. A well-known mechanism
that tumors utilize to evade antitumor host-response comprises the
transcriptional silencing of molecules of the tumor recognition
complex, such as class-I molecules [64]. In fact, a recent clinical
study on renal cancer and melanoma utilizing a DNA methylation
inhibitor along with high-dose interleukin-2 achieved encouraging
response rates attributed to facilitation of the immune response
against the tumor [65]. In this regard, we have gathered data
(submitted for publication) that hydralazine and valproate not only
up-regulate HLA-class-I molecules, but also tumor-associated
MAGE- and GAGE-family antigens in cervical cancer-cell lines,
which increases the immune recognition and killing of these
cervical cancer-cell lines by HPV peptide-stimulated autologous T
cells. Additionally of note is up-regulation of the antimetastatic
gene product NM23, which is frequently methylated and silenced
in patients with breast cancer [66].
At least_but not in the least_we were surprised by large number
of up-regulated genes belonging to the mitochondrial oxidative
phosphorylation (OXPHOS) system, with a total of 18 members,
the majority of these from complex I. The OXPHOS system
consists of five multiprotein complexes, the individual subunits of
which are encoded either by the mitochondrial or by the nuclear
genome. Defects in the OXPHOS system result in devastating
diseases, and in recent years its role in cancer has begun to be
studied [67]. For example, the NADH dehydrogenase (ubiqui-
none) 1 alpha subcomplex 13 is a gene known to be down-
regulated in basal cell carcinomas [68]. This gene, also
denominated NDUFA13 or GRIM19, was initially identified as
a pro-apoptotic gene mediating retinoid antitumor effects and
indispensable for proper assembling and functioning of complex I
of this pathway [69]. In addition, it has been demonstrated that
NADH dehydrogenase plays an important role in generating ROS
during doxorubicin treatment, and its down-regulation has been
found in doxorubicin-resistant A431 cells [70]. This was one of the
Table 6. Selected up-regulated genes
..................................................................................................................................................
Gene nomenclature Symbol Fold up-regulated
Tumor protein p53 (Li-Fraumeni syndrome) TP53 7.76739051
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 NDUFA13 8.35606086
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa NDUFA3 8.10452144
NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15 kDa NDUFS5 8.09082978
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kDa NDUFA1 8.08146401
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7 kDa NDUFB1 8.08030825
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDa NDUFA5 8.04508688
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22 kDa NDUFB10 7.923889
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa NDUFB2 7.86803475
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa NDUFA6 7.86404551
Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5 kDa UQCRQ 11.5153711
Cytochrome b5 reductase 3 CYB5R3 6.3771685
Ubiquinol-cytochrome c reductase binding protein UQCRB 5.25097865
Cytochrome P450, family 4, subfamily Z, polypeptide 1 CYP4Z1 3.95720644
Cytochrome c oxidase subunit VIIc COX7C 3.54327802
Cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) COX6B1 3.24018981
Cytochrome P450, family 4, subfamily X, polypeptide 1 CYP4X1 2.62403203
Cytochrome b5 reductase 1 CYB5R1 2.35704124
Cytochrome P450, family 2, subfamily A, polypeptide 7 CYP2A7 2.28545699
Major histocompatibility complex, class I, A HLA-A 8.28725704
Major histocompatibility complex, class II, DO beta HLA-DOB 8.06028024
Major histocompatibility complex, class I, B HLA-B 8.02382794
Interferon-induced transmembrane protein 2 (1–8D) IFITM2 8.01432864
Interferon-related developmental regulator 1 IFRD1 7.98237098
Interferon regulatory factor 7 IRF7 7.83758943
Non-metastatic cells 1, protein (NM23A) expressed in NME1 7.8821744
Gene nomenclature Symbol Fold down-regulated
ATP-binding cassette, sub-family B (MDR/TAP), member 5 ABCB5 26.072
doi:10.1371/journal.pone.0000098.t006
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PLoS ONE | www.plosone.org 9 December 2006 | Issue 1 | e98two individual genes we assessed in the pre-and post-treatment
biopsies by RT-PCR in a single patient corroborating the up-
regulation observed in the microarray analysis.
Regarding down-regulated genes, in this work we solely point
out that ATP-binding cassette, sub-family B (MDR/TAP),
member 5 was down-regulated by hydralazine and magnesium
valproate treatment. Interestingly, ABCB5 is a novel drug
transporter and a chemoresistance mediator identified in human
melanoma and instinctively present in a subset of chemoresistant,
stem cell phenotype-expressing tumor cells among melanoma bulk
populations, indicating that these chemoresistant cells can be
specifically targeted via ABCB5 to enhance cytotoxic efficacy [69].
Conclusion
In this proof-of-concept study, we demonstrate that treatment with
hydralazine and magnesium valproate exerts its proposed
molecular effects of DNA demethylation, HDAC inhibition, and
gene reactivation in primary tumors of patients with breast cancer.
Importantly, this doxorubicin- and cyclophosphamide-associated
treatment is safe and well-tolerated, and appears to increase the
efficacy of chemotherapy. A randomized phase III study is
ongoing to support the efficacy of the so-called epigenetic or
transcriptional cancer therapy.
SUPPORTING INFORMATION
Table S1 Up-regulated genes
Found at: doi:10.1371/journal.pone.0000098.s001 (0.17 MB
XLS)
Table S2 Down-regulated genes
Found at: doi:10.1371/journal.pone.0000098.s002 (0.03 MB
XLS)
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